NICE has announced a collaboration with an organisation representing UK life sciences, to improve communications between the cost-effectiveness body and industry.
Healthcare professionals and patient groups have written to Vertex’s CEO Jeffrey Leiden in a bid to resolve a funding row over cystic fibrosis drugs, as UK MPs prepare to hold a public hear
Don’t expect the US government’s war on drug pricing to go away any time soon – for once president Trump and his rivals, the Democrat party, agree on something, and both have had some stron
The UK government has published a new five year plan aimed at tackling antimicrobial resistance (AMR), including a new NHS reimbursement scheme backed by NICE to encourage pharma to develop
US politicians from the resurgent Democratic party have launched a probe into “unsustainable” drug price rises, prompting their shares to drop suddenly.
Market access has become a key focus for governments across the globe in 2018 – though as ever a balance between what is good for the industry and what is good for countries and their healt